Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations

Erick Riquelme, Carmen Behrens, Heather Y. Lin, George Simon, Vassiliki Papadimitrakopoulou, Julie Izzo, Cesar Moran, Neda Kalhor, J. Jack Lee, John D. Minna, Ignacio I. Wistuba

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

EZH2 overexpression promotes cancer by increasing histone methylation to silence tumor suppressor genes, but how EZH2 levels become elevated in cancer is not understood. In this study, we investigated the mechanisms by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS. In cells harboring KRASG12C and KRASG12D mutations, EZH2 expression was modulated by MEK-ERK and PI3K/AKT signaling, respectively. Accordingly, MEK-ERK depletion decreased EZH2 expression in cells harboring the KRASG12C mutation, whereas PI3K/AKT depletion decreased EZH2 expression, EZH2 phosphorylation, and STAT3 activity in KRASG12D-mutant cell lines. Combined inhibition of EZH2 and MEK-ERK or PI3K/AKT increased the sensitivity of cells with specific KRAS mutations to MEK-ERK and PI3K/AKT- targeted therapies. Our work defines EZH2 as a downstream effector of KRAS signaling and offers a rationale for combining EZH2 inhibitory strategies with MEK-ERK-or PI3K/AKT-Targeted therapies to treat lung cancer patients, as stratified into distinct treatment groups based on specific KRAS mutations.

Original languageEnglish (US)
Pages (from-to)675-685
Number of pages11
JournalCancer Research
Volume76
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Oncogenes
Lung Neoplasms
Mutation
Tumor Suppressor Genes
Non-Small Cell Lung Carcinoma
Histones
Methylation
Neoplasms
Therapeutics
Phosphorylation
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Riquelme, E., Behrens, C., Lin, H. Y., Simon, G., Papadimitrakopoulou, V., Izzo, J., ... Wistuba, I. I. (2016). Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Research, 76(3), 675-685. https://doi.org/10.1158/0008-5472.CAN-15-1141

Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. / Riquelme, Erick; Behrens, Carmen; Lin, Heather Y.; Simon, George; Papadimitrakopoulou, Vassiliki; Izzo, Julie; Moran, Cesar; Kalhor, Neda; Jack Lee, J.; Minna, John D.; Wistuba, Ignacio I.

In: Cancer Research, Vol. 76, No. 3, 01.02.2016, p. 675-685.

Research output: Contribution to journalArticle

Riquelme, E, Behrens, C, Lin, HY, Simon, G, Papadimitrakopoulou, V, Izzo, J, Moran, C, Kalhor, N, Jack Lee, J, Minna, JD & Wistuba, II 2016, 'Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations', Cancer Research, vol. 76, no. 3, pp. 675-685. https://doi.org/10.1158/0008-5472.CAN-15-1141
Riquelme, Erick ; Behrens, Carmen ; Lin, Heather Y. ; Simon, George ; Papadimitrakopoulou, Vassiliki ; Izzo, Julie ; Moran, Cesar ; Kalhor, Neda ; Jack Lee, J. ; Minna, John D. ; Wistuba, Ignacio I. / Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. In: Cancer Research. 2016 ; Vol. 76, No. 3. pp. 675-685.
@article{4262879008294997a634660466f9bf02,
title = "Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations",
abstract = "EZH2 overexpression promotes cancer by increasing histone methylation to silence tumor suppressor genes, but how EZH2 levels become elevated in cancer is not understood. In this study, we investigated the mechanisms by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS. In cells harboring KRASG12C and KRASG12D mutations, EZH2 expression was modulated by MEK-ERK and PI3K/AKT signaling, respectively. Accordingly, MEK-ERK depletion decreased EZH2 expression in cells harboring the KRASG12C mutation, whereas PI3K/AKT depletion decreased EZH2 expression, EZH2 phosphorylation, and STAT3 activity in KRASG12D-mutant cell lines. Combined inhibition of EZH2 and MEK-ERK or PI3K/AKT increased the sensitivity of cells with specific KRAS mutations to MEK-ERK and PI3K/AKT- targeted therapies. Our work defines EZH2 as a downstream effector of KRAS signaling and offers a rationale for combining EZH2 inhibitory strategies with MEK-ERK-or PI3K/AKT-Targeted therapies to treat lung cancer patients, as stratified into distinct treatment groups based on specific KRAS mutations.",
author = "Erick Riquelme and Carmen Behrens and Lin, {Heather Y.} and George Simon and Vassiliki Papadimitrakopoulou and Julie Izzo and Cesar Moran and Neda Kalhor and {Jack Lee}, J. and Minna, {John D.} and Wistuba, {Ignacio I.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-15-1141",
language = "English (US)",
volume = "76",
pages = "675--685",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations

AU - Riquelme, Erick

AU - Behrens, Carmen

AU - Lin, Heather Y.

AU - Simon, George

AU - Papadimitrakopoulou, Vassiliki

AU - Izzo, Julie

AU - Moran, Cesar

AU - Kalhor, Neda

AU - Jack Lee, J.

AU - Minna, John D.

AU - Wistuba, Ignacio I.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - EZH2 overexpression promotes cancer by increasing histone methylation to silence tumor suppressor genes, but how EZH2 levels become elevated in cancer is not understood. In this study, we investigated the mechanisms by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS. In cells harboring KRASG12C and KRASG12D mutations, EZH2 expression was modulated by MEK-ERK and PI3K/AKT signaling, respectively. Accordingly, MEK-ERK depletion decreased EZH2 expression in cells harboring the KRASG12C mutation, whereas PI3K/AKT depletion decreased EZH2 expression, EZH2 phosphorylation, and STAT3 activity in KRASG12D-mutant cell lines. Combined inhibition of EZH2 and MEK-ERK or PI3K/AKT increased the sensitivity of cells with specific KRAS mutations to MEK-ERK and PI3K/AKT- targeted therapies. Our work defines EZH2 as a downstream effector of KRAS signaling and offers a rationale for combining EZH2 inhibitory strategies with MEK-ERK-or PI3K/AKT-Targeted therapies to treat lung cancer patients, as stratified into distinct treatment groups based on specific KRAS mutations.

AB - EZH2 overexpression promotes cancer by increasing histone methylation to silence tumor suppressor genes, but how EZH2 levels become elevated in cancer is not understood. In this study, we investigated the mechanisms by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS. In cells harboring KRASG12C and KRASG12D mutations, EZH2 expression was modulated by MEK-ERK and PI3K/AKT signaling, respectively. Accordingly, MEK-ERK depletion decreased EZH2 expression in cells harboring the KRASG12C mutation, whereas PI3K/AKT depletion decreased EZH2 expression, EZH2 phosphorylation, and STAT3 activity in KRASG12D-mutant cell lines. Combined inhibition of EZH2 and MEK-ERK or PI3K/AKT increased the sensitivity of cells with specific KRAS mutations to MEK-ERK and PI3K/AKT- targeted therapies. Our work defines EZH2 as a downstream effector of KRAS signaling and offers a rationale for combining EZH2 inhibitory strategies with MEK-ERK-or PI3K/AKT-Targeted therapies to treat lung cancer patients, as stratified into distinct treatment groups based on specific KRAS mutations.

UR - http://www.scopus.com/inward/record.url?scp=84958231381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958231381&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-1141

DO - 10.1158/0008-5472.CAN-15-1141

M3 - Article

C2 - 26676756

AN - SCOPUS:84958231381

VL - 76

SP - 675

EP - 685

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -